Skip to main content

Profile

Loading content
 Simeng Lin

Simeng Lin

PhD Student

 RILD Building 

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK

Overview

Simeng is a gastroenterology trainee doctor in the South West, with an interest in inflammatory bowel disease (IBD). She has been awarded a Wellcome GW4-CAT fellowship and is currently pursuing her PhD under the supervision of Prof Jonathan Mill, Dr Eilis Hannon and Dr Tariq Ahmad at the University of Exeter and Dr Gareth Jones at the University of Bristol.

During her PhD, Simeng’s project will focus on using genomic approaches to understand the molecular mechanisms of immunogenicity to biologic therapies

Qualifications

  • MBChB 2012: University of Sheffield
  • PGCert (Genomic Medicine) 2020: University of Exeter

Research

Research interests

Simeng’s academic interest in gastroenterology began during her undergraduate studies at the University of Sheffield, where she published two papers on functional bowel conditions, and was a sub-investigator in a number of gastroenterology clinical trials during her specialty training. She was subsequently awarded a Wellcome-funded Clinical Primer at the Translational Research Exchange @ Exeter (TREE) where she developed skills in data analytics, alongside obtaining a Postgraduate Certificate in Genomic Medicine at the University of Exeter.

Simeng hopes to utilise her clinical, genomic and data analytic skill sets to further understand the molecular mechanisms surrounding treatment outcomes in patients with IBD in her PhD.

 

Research projects

  • Using genomic approaches to understand immunogenicity of biologic drugs in inflammatory bowel disease

Publications

Key publications | Publications by category | Publications by year

Publications by category


Journal articles

Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Arkir Z, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, et al (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J Crohns Colitis, 16(3), 389-397. Abstract.  Author URL.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun, 13(1). Abstract.  Author URL.  Full text.
Chee D, Nice R, Hamilton B, Jones E, Hawkins S, Redstone C, Cairnes V, Pohl K, Chanchlani N, Lin S, et al (2022). Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. J Crohns Colitis, 16(2), 190-198. Abstract.  Author URL.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, et al (2021). Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 70(5), 865-875. Abstract.
Chanchlani N, Lin S, Thomas A, Hamilton B, Nice R, Chee D, Kennedy N, Goodhand J, Ahmad T (2021). HMO-4 Immunogenicity to second anti-TNF therapy (IMSAT): implications for sequencing of biologic therapy. Gut, 70(Suppl 4), a31-a32.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 70(10), 1884-1893. Abstract.  Author URL.
Kennedy N, Lin S, Goodhand J, Powell N, Ahmad T (2021). OFR-8 Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Gut, 70(Suppl 4), a3-a4.
Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, et al (2020). Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. J Crohns Colitis, 14(12), 1653-1661. Abstract.  Author URL.  Full text.
Lin S, Chanchlani N, Invergo BM, Anderson MW, Guay HM, Reppell M, Butler JW, Goodhand JR, Ahmad T, Kennedy NA, et al (2020). DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: a pilot serum proteomic analysis of the PANTS cohort. Journal of Crohn's and Colitis, 14(Supplement_1), s067-s068.
Gordon C, Chee D, Hamilton B, Chanchlani N, Heerasing NM, Hendy P, Lin S, Wesley E, Daniels I, Goodhand JR, et al (2020). P250 Root cause analysis to identify missed opportunities for the diagnosis of colorectal cancer in inflammatory bowel disease. Journal of Crohn's and Colitis, 14(Supplement_1), s273-s275.
Walker GJ, Chanchlani N, Thomas A, Lin S, Moore L, Heerasing NM, Hendy P, Abdelrahim M, Mole S, Perry MH, et al (2020). Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child, 105(10), 957-963. Abstract.  Author URL.
Walker GJ, Lin S, Chanchlani N, Thomas A, Hendy P, Heerasing N, Moore L, Green HD, Chee D, Bewshea C, et al (2020). Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology & Therapeutics, 52(3), 471-480.
Gordon C, Chee D, Hamilton B, Chanchlani N, Heerasing NM, Hendy P, Lin S, Wesley E, Daniels I, Goodhand JR, et al (2020). Root cause analysis to identify missed opportunities for the diagnosis of colorectal cancer in inflammatory bowel disease. JOURNAL OF CROHNS & COLITIS, 14, S273-S275. Author URL.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology Full text.
Lin S, Sanders DS, Gleeson JT, Osborne C, Messham L, Kurien M (2016). Long-term outcomes in patients diagnosed with bile-acid diarrhoea. European Journal of Gastroenterology & Hepatology, 28(2), 240-245.
Lin S, Kurien M, Aziz I, Winfield S, Rugg N, Kelsall A, Leeds JS, Sanders DS (2013). PTU-134 Prevalance and Investigational Pathways of Patients with Constipation Predominant Irritable Bowel Syndrome. Gut, 62(Suppl 1).
Ibrahim W, Lin S (2013). Reducing time spent by junior doctors on call performing routine tasks at weekends. BMJ Open Quality, 2(1).
Lin S, Kurien M, Leeds JS, Sanders DS (2012). PWE-056 Prospective evaluation of 403 patients with diarrhoea predominant irritable bowel syndrome (D-IBS) fulfilling Rome II criteria. Gut, 61(Suppl 2).
Barratt SM, Leeds JS, Lin S, Wilson H, Sanders DS (2010). PTH-084 Gluten-free diet adherent: but at what cost?. Gut, 59(Suppl 1).
Barratt SM, Leeds JS, Lobo AJ, Mcalindon ME, Robinson K, Wilson H, Lin S, Sanders DS (2010). PWE-025 Comparing quality of life in coeliac disease and inflammatory bowel disease: a paradigm shift in our perceptions?. Gut, 59(Suppl 1).

Conferences

Lin S, Bewshea C, Chanchlani N, Chee D, Pollok RC, Kennedy NA, Ahmad T, Goodhand JR (2021). Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic.  Author URL.
Chee D, Hamilton B, Cairnes V, Lin S, Chanchlani N, Ahmad T, Goodhand J, Kennedy N (2021). Development of a new Inflammatory Bowel Disease Patient Identifier shortens time to clinic review and initiation of treatment.  Author URL.
Chanchlani N, Lin S, Thomas A, Hamilton B, Nice R, Chee D, Kennedy N, Goodhand J, Ahmad T, Investigators IMSATS, et al (2021). Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy.  Author URL.
Windak H, Cairnes V, Chanchlani N, Chee D, Hamilton B, Heerasing N, Hendy P, Lin S, Kennedy N, Goodhand J, et al (2021). OUTCOMES OF GP OUTREACH PROGRAMME OFFERING COLONOSCOPIC SURVEILLANCE FOR IBD PATIENTS MANAGED IN PRIMARY CARE.  Author URL.
Nice R, Chanchlani N, Kennedy NA, Green HD, Lin S, Gordon C, Chee D, Hamilton B, Bewshea C, Goodhand J, et al (2021). POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE.  Author URL.
Walker G, Lin S, Thomas A, Chanchlani N, Moore L, Hendy P, Heerasing N, Green H, Mole S, Bewshea C, et al (2019). PROSPECTIVE COHORT TO IDENTIFY FACTORS ASSOCIATED WITH DIAGNOSTIC DELAY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.  Author URL.
Walker G, Lin S, Chanchlani N, Thomas A, Moore L, Hendy P, Heerasing N, Green H, Bewshea C, Goodhand J, et al (2019). Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease.  Author URL.

Publications by year


2022

Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Arkir Z, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, et al (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J Crohns Colitis, 16(3), 389-397. Abstract.  Author URL.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun, 13(1). Abstract.  Author URL.  Full text.
Chee D, Nice R, Hamilton B, Jones E, Hawkins S, Redstone C, Cairnes V, Pohl K, Chanchlani N, Lin S, et al (2022). Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. J Crohns Colitis, 16(2), 190-198. Abstract.  Author URL.

2021

Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, et al (2021). Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 70(5), 865-875. Abstract.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2021). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients.
Lin S, Bewshea C, Chanchlani N, Chee D, Pollok RC, Kennedy NA, Ahmad T, Goodhand JR (2021). Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic.  Author URL.
Chee D, Hamilton B, Cairnes V, Lin S, Chanchlani N, Ahmad T, Goodhand J, Kennedy N (2021). Development of a new Inflammatory Bowel Disease Patient Identifier shortens time to clinic review and initiation of treatment.  Author URL.
Chanchlani N, Lin S, Thomas A, Hamilton B, Nice R, Chee D, Kennedy N, Goodhand J, Ahmad T (2021). HMO-4 Immunogenicity to second anti-TNF therapy (IMSAT): implications for sequencing of biologic therapy. Gut, 70(Suppl 4), a31-a32.
Chanchlani N, Lin S, Thomas A, Hamilton B, Nice R, Chee D, Kennedy N, Goodhand J, Ahmad T, Investigators IMSATS, et al (2021). Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy.  Author URL.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings F, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 70(10), 1884-1893. Abstract.  Author URL.
Kennedy N, Lin S, Goodhand J, Powell N, Ahmad T (2021). OFR-8 Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Gut, 70(Suppl 4), a3-a4.
Windak H, Cairnes V, Chanchlani N, Chee D, Hamilton B, Heerasing N, Hendy P, Lin S, Kennedy N, Goodhand J, et al (2021). OUTCOMES OF GP OUTREACH PROGRAMME OFFERING COLONOSCOPIC SURVEILLANCE FOR IBD PATIENTS MANAGED IN PRIMARY CARE.  Author URL.
Nice R, Chanchlani N, Kennedy NA, Green HD, Lin S, Gordon C, Chee D, Hamilton B, Bewshea C, Goodhand J, et al (2021). POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE.  Author URL.

2020

Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, et al (2020). Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. J Crohns Colitis, 14(12), 1653-1661. Abstract.  Author URL.  Full text.
Lin S, Chanchlani N, Invergo BM, Anderson MW, Guay HM, Reppell M, Butler JW, Goodhand JR, Ahmad T, Kennedy NA, et al (2020). DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: a pilot serum proteomic analysis of the PANTS cohort. Journal of Crohn's and Colitis, 14(Supplement_1), s067-s068.
Gordon C, Chee D, Hamilton B, Chanchlani N, Heerasing NM, Hendy P, Lin S, Wesley E, Daniels I, Goodhand JR, et al (2020). P250 Root cause analysis to identify missed opportunities for the diagnosis of colorectal cancer in inflammatory bowel disease. Journal of Crohn's and Colitis, 14(Supplement_1), s273-s275.
Walker GJ, Chanchlani N, Thomas A, Lin S, Moore L, Heerasing NM, Hendy P, Abdelrahim M, Mole S, Perry MH, et al (2020). Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child, 105(10), 957-963. Abstract.  Author URL.
Walker GJ, Lin S, Chanchlani N, Thomas A, Hendy P, Heerasing N, Moore L, Green HD, Chee D, Bewshea C, et al (2020). Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology & Therapeutics, 52(3), 471-480.
Gordon C, Chee D, Hamilton B, Chanchlani N, Heerasing NM, Hendy P, Lin S, Wesley E, Daniels I, Goodhand JR, et al (2020). Root cause analysis to identify missed opportunities for the diagnosis of colorectal cancer in inflammatory bowel disease. JOURNAL OF CROHNS & COLITIS, 14, S273-S275. Author URL.

2019

Walker G, Lin S, Thomas A, Chanchlani N, Moore L, Hendy P, Heerasing N, Green H, Mole S, Bewshea C, et al (2019). PROSPECTIVE COHORT TO IDENTIFY FACTORS ASSOCIATED WITH DIAGNOSTIC DELAY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.  Author URL.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology Full text.
Walker G, Lin S, Chanchlani N, Thomas A, Moore L, Hendy P, Heerasing N, Green H, Bewshea C, Goodhand J, et al (2019). Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease.  Author URL.

2016

Lin S, Sanders DS, Gleeson JT, Osborne C, Messham L, Kurien M (2016). Long-term outcomes in patients diagnosed with bile-acid diarrhoea. European Journal of Gastroenterology & Hepatology, 28(2), 240-245.

2013

Lin S, Kurien M, Aziz I, Winfield S, Rugg N, Kelsall A, Leeds JS, Sanders DS (2013). PTU-134 Prevalance and Investigational Pathways of Patients with Constipation Predominant Irritable Bowel Syndrome. Gut, 62(Suppl 1).
Ibrahim W, Lin S (2013). Reducing time spent by junior doctors on call performing routine tasks at weekends. BMJ Open Quality, 2(1).

2012

Lin S, Kurien M, Leeds JS, Sanders DS (2012). PWE-056 Prospective evaluation of 403 patients with diarrhoea predominant irritable bowel syndrome (D-IBS) fulfilling Rome II criteria. Gut, 61(Suppl 2).

2010

Barratt SM, Leeds JS, Lin S, Wilson H, Sanders DS (2010). PTH-084 Gluten-free diet adherent: but at what cost?. Gut, 59(Suppl 1).
Barratt SM, Leeds JS, Lobo AJ, Mcalindon ME, Robinson K, Wilson H, Lin S, Sanders DS (2010). PWE-025 Comparing quality of life in coeliac disease and inflammatory bowel disease: a paradigm shift in our perceptions?. Gut, 59(Suppl 1).

Simeng_Lin Details from cache as at 2022-07-01 22:39:19

Refresh publications

Teaching

Supervision / Group

Back | Edit Profile